Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Metrics to compare | CGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCGTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.2x | −3.1x | −0.5x | |
PEG Ratio | −0.06 | 0.02 | 0.00 | |
Price/Book | 3.4x | 3.4x | 2.6x | |
Price / LTM Sales | - | 2.2x | 3.3x | |
Upside (Analyst Target) | - | 98.2% | 45.1% | |
Fair Value Upside | Unlock | 22.0% | 7.4% | Unlock |